Safety Information
Rilpivirine: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.
- Levitra is available in 10 mg and 20 mg tablets.
- The medication is not an aphrodisiac; it enhances ability when sexually stimulated.
- Vardenafil is a PDE5 inhibitor class drug.
- It can be used by men with diabetes-related erectile issues.
- Levitra may cause dizziness; avoid driving after taking.
- The medication is approved by the FDA for ED treatment.
- Do not use if you have severe liver or kidney problems.
- Vardenafil should be stored at room temperature, away from moisture.
- It is not suitable for women or children.
- Consult your doctor for potential drug interactions.
Riociguat: (Contraindicated) Use of riociguat and vardenafil is contraindicated due to the risk of hypotension.
| Parameter | Value | Notes |
|---|---|---|
| Onset of Action | 25-60 minutes | Typically 30-45 minutes |
| Duration of Effect | Up to 5 hours | Varies with dose and individual |
| Half-life | Approximately 4-5 hours | Determines dosing frequency |
| Time to Peak Concentration | About 60 minutes | After oral administration |
Discontinue riociguat at least 24 hours prior to vardenafil administration.
| Brand Name | Active Ingredient | Medication Type | Typical Dosage | Available Forms |
|---|---|---|---|---|
| Levitra | Vardenafil | PDE5 Inhibitor | 5 mg, 10 mg, 20 mg | Tablets |
| Staxyn | Vardenafil ODT | PDE5 Inhibitor | 10 mg | Orally Disintegrating Tablets |
| Vidalista | Tadalafil (comparison) | PDE5 Inhibitor | 2.5 mg, 5 mg, 10 mg | Tablets |
Monitor for signs and symptoms of hypotension during transition of therapy.
| Condition | Caution | Reason |
|---|---|---|
| Use with Nitrates | Contraindicated | Risk of severe hypotension |
| Severe Liver Impairment | Use with caution | Metabolism may be affected |
| Heart Disease | Consult doctor before use | Potential cardiovascular risks |
| Retinitis Pigmentosa | Avoid | Possible risk of vision loss |
| Hypotension or Hypertension | Caution or avoid | Blood pressure effects |
PDE5 inhibitors, including vardenafil, may potentiate the hypotensive effects of riociguat.
CRD commentary
A suitable time interval after vardenafil dosing for the safe administration of nitrates has not been determined. In addition, vardenafil may potentiate the nitric oxide-mediated platelet anti-aggregatory effect of nitroprusside. Ofloxacin: (Moderate) Concomitant use of ofloxacin and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Olanzapine: (Moderate) Concomitant use of vardenafil and olanzapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Olanzapine; Fluoxetine: (Moderate) Concomitant use of vardenafil and fluoxetine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.
How much do Levitra and Stendra cost?
(Moderate) Concomitant use of vardenafil and olanzapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Olanzapine; Samidorphan: (Moderate) Concomitant use of vardenafil and olanzapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ondansetron: (Major) Concomitant use of ondansetron and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Osilodrostat: (Moderate) Concomitant use of vardenafil and osilodrostat may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Osimertinib: (Major) Concomitant use of vardenafil and osimertinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP).
What are the most common side effects for Stendra?
Oxaliplatin: (Major) Concomitant use of vardenafil and oxaliplatin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ozanimod: (Major) In general, do not initiate ozanimod in patients taking vardenafil due to the risk of additive bradycardia, QT prolongation, and torsade de pointes (TdP). If treatment initiation is considered, seek liquid levitra advice from a cardiologist. Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. Risperidone: (Moderate) Concomitant use of vardenafil and risperidone may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.
- Levitra is manufactured by Bayer Pharmaceuticals.
- It is available in both tablet and generic forms.
- The drug can be prescribed for men aged 18 and above.
- Levitra's active ingredient is vardenafil hydrochloride.
- It helps achieve erections suitable for sexual activity.
- Taking fatty meals may delay the drug's onset.
- Levitra does not protect against sexually transmitted diseases.
- Use with caution if you have heart conditions.
- It is essential to inform your doctor of all medications.
- Vardenafil does not cure ED; it manages symptoms.
Ritlecitinib: (Major) Do not use vardenafil orally disintegrating tablets with ritlecitinib due to increased vardenafil exposure;
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Professional | 20mg | 360 + 6 Pills | 914.63€ 871.08€ | |
| Levitra Generic | 40mg | 90 + 6 Pills | 234.73€ 223.55€ | |
| Levitra Soft Tabs | 20mg | 360 + 20 Pills | 682.21€ 649.72€ | |
| Levitra Original | 20mg | 76 + 4 Pills | 344.39€ 327.99€ | |
| Levitra Generic | 10mg | 90 + 8 Pills | 150.58€ 143.41€ | |
| Levitra Soft Tabs | 20mg | 270 + 10 Pills | 521.78€ 496.93€ | |
| Levitra Generic | 20mg | 60 + 6 Pills | 131.11€ 124.87€ | |
| Levitra Generic | 10mg | 30 + 4 Pills | 62.39€ 59.42€ | |
| Levitra Original | 20mg | 48 + 4 Pills | 235.14€ 223.94€ | |
| Levitra Original | 20mg | 22 + 2 Pills | 138.55€ 131.95€ | |
| Levitra Original | 20mg | 14 + 2 Pills | 102.27€ 97.40€ | |
| Levitra Original | 20mg | 4 Pills | 45.87€ 43.69€ | |
| Levitra Generic | 60mg | 30 + 2 Pills | 109.43€ 104.22€ | |
| Levitra Generic | 10mg | 60 + 6 Pills | 112.98€ 107.60€ | |
| Levitra Generic | 60mg | 90 + 6 Pills | 291.82€ 277.92€ | |
| Levitra Generic | 60mg | 10 Pills | 47.42€ 45.16€ |
do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.
Vardenafil (Generic Levitra®) FAQs
Promethazine; Dextromethorphan: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Promethazine; Phenylephrine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Quetiapine: (Major) Concomitant use of vardenafil and quetiapine increases the risk of QT/QTc prolongation and torsade de cheapest generic levitra online pointes (TdP). Quinidine: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Quinine: (Major) Concomitant use of vardenafil and quinine increases the risk of QT/QTc prolongation and torsade de pointes (TdP).
ED Prescriptions for $1-2 Per Pill
Quizartinib: (Major) Concomitant use of quizartinib and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ranolazine: (Major) Concomitant use of vardenafil and ranolazine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Relugolix: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., relugolix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Relugolix; Estradiol; Norethindrone acetate: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., relugolix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ribociclib: (Major) Concurrent use of vardenafil orally disintegrating tablets with ribociclib should be avoided due to increased vardenafil exposure. Vardenafil is primarily metabolized by CYP3A; ritlecitinib is a moderate CYP3A inhibitor.
How RedBox Rx can help
Pimavanserin: (Major) Concomitant use of vardenafil and pimavanserin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Pimozide: (Contraindicated) Avoid concomitant use of vardenafil and pimozide due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Pitolisant: (Major) Concomitant use of vardenafil and pitolisant increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ponesimod: (Major) In general, do not initiate ponesimod in patients taking vardenafil due to the risk of additive bradycardia, QT prolongation, and torsade de pointes (TdP). Ponesimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays.
Pharmacotherapy for erectile dysfunction
Ponesimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia. Posaconazole: (Contraindicated) The concurrent use of posaconazole with drugs that are associated with QT prolongation and are also CYP3A4 substrates, such as vardenafil, is contraindicated. Posaconazole is associated with QT prolongation, and vardenafil may cause QT prolongation at both therapeutic and supratherapeutic doses. Elevated plasma concentrations of vardenafil may also increase the risk for other vardenafil-related adverse events, such as prolonged erection or potential for syncope. Prazosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil.
How were the studies combined?
Primaquine: (Moderate) Concomitant use of vardenafil and primaquine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Procainamide: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Prochlorperazine: cost levitra costco (Minor) Use vardenafil with caution in combination with prochlorperazine due to increased risk of QT prolongation. Prochlorperazine is also associated with a possible risk for QT prolongation. Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ritonavir: (Major) Do not use vardenafil orally disintegrating tablets with ritonavir due to increased vardenafil exposure;
Record Status
If use of vardenafil oral tablets and ribociclib is required, do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Also, coadministration of ribociclib with vardenafil should be avoided if possible due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Vardenafil can produce QT prolongation at both therapeutic and supratherapeutic doses. Ribociclib; Letrozole: (Major) Concurrent use of vardenafil orally disintegrating tablets with ribociclib should be avoided due to increased vardenafil exposure. do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.
Database entry date
Pacritinib: (Major) Concomitant use of pacritinib and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Paliperidone: (Major) Concomitant use of vardenafil and paliperodone increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Panobinostat: (Major) QT prolongation has been reported with panobinostat therapy in patients with multiple myeloma in a clinical trial; use of panobinostat with other agents that prolong the QT interval is not recommended. Obtain an electrocardiogram at baseline and periodically during treatment. Hold panobinostat if the QTcF increases to >= 480 milliseconds during therapy; permanently discontinue if QT prolongation does not resolve.
How to Take Vardenafil
Drugs with a possible risk for QT prolongation and torsade de pointes that should be used cautiously and with close monitoring with panobinostat include vardenafil. Pasireotide: (Moderate) Concomitant use of vardenafil and pasireotide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Pazopanib: (Major) Concomitant use of vardenafil and pazopanib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Pentamidine: (Major) Concomitant use of vardenafil and pentamidine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Perphenazine: (Minor) Use vardenafil with caution in combination with perphenazine due to increased risk of QT prolongation.
Phosphodiesterase Type 5 Inhibitors: The Day After
Perphenazine is associated with a possible risk for QT prolongation. Perphenazine; Amitriptyline: (Minor) Use vardenafil with caution in combination with perphenazine due to increased risk of QT prolongation. Phenoxybenzamine: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil. Phentolamine: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil. Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Romidepsin: (Moderate) Concomitant use of vardenafil and romidepsin may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.